<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00563056</url>
  </required_header>
  <id_info>
    <org_study_id>FLT3505</org_study_id>
    <secondary_id>2007-001634-13</secondary_id>
    <nct_id>NCT00563056</nct_id>
  </id_info>
  <brief_title>An Open, Randomised, Parallel Group Multicentre Study to Compare the Efficacy and Safety of Flutiform® pMDI vs Fluticasone pMDI Plus Formoterol DPI in Adolescent and Adult Subjects With Mild to Moderate-severe Persistent, Reversible Asthma</brief_title>
  <official_title>Open, Randomised, Parallel Group Multicentre Study to Compare the Efficacy &amp; Safety of Flutiform® pMDI vs Fluticasone pMDI Plus Formoterol DPI in Adolescent &amp; Adult Subjects With Mild to Moderate-severe Persistent, Reversible Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mundipharma Research Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mundipharma Research Limited</source>
  <brief_summary>
    <textblock>
      Flutiform® compared with the individual components Flixotide® (Fluticasone) and Foradil®&#xD;
      (Formoterol) in adolescent and adult patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a study involving a 12 week treatment phase. During the treatment phase subjects&#xD;
      receive Flutiform® or Flixotiole® and Foradil® as individual componements. Efficacy will be&#xD;
      assessed by lung function tests and asthma symptoms, sleep disturbance. Safety will be&#xD;
      assessed by adverse events, vital signs, lab tests and ECGs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of mean Forced Expriatory Volume in the 1st second (FEV1) values.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Discontinuation, PEFR, rescue medication use, asthma symptom scores, sleep disturbance, AQLQ, exacerbations, patient acceptance</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">227</enrollment>
  <condition>Asthma Bronchiale</condition>
  <arm_group>
    <arm_group_label>Flutiform</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 puffs 50/5 or 125/5 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flixotide plus Foradil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Flixotide 2 puffs 50 or 125 mcg; Foradil 1 puff 12 mcg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flutiform</intervention_name>
    <arm_group_label>Flutiform</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flixotide plus Foradil</intervention_name>
    <arm_group_label>Flixotide plus Foradil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Male or female subjects at least 12 years or older (females less than one year&#xD;
             post-menopausal must have a negative serum or urine pregnancy test recorded at the&#xD;
             screening visit prior to the first dose of study medication, be non-lactating, and&#xD;
             willing to use adequate and highly effective methods of contraception throughout the&#xD;
             study if they are sexually active. A highly effective method of birth control is&#xD;
             defined as those which result in a low failure rate (i.e. less than 1% per year) when&#xD;
             used consistently and correctly such as sterilization, implants, injectables, combined&#xD;
             oral contraceptives, some IUDs (Intrauterine Device, hormonal), sexual abstinence or&#xD;
             vasectomised partner).&#xD;
&#xD;
          2. Known history of mild to moderate-severe persistent, reversible asthma for ≥ 6 months&#xD;
             prior to the screening visit.&#xD;
&#xD;
          3. Demonstrate a FEV1 of ≥40% to ≤85% for predicted normal values (Quanjer et al, 19931)&#xD;
             during the screening phase following appropriate withholding of asthma medications (if&#xD;
             applicable).&#xD;
&#xD;
               -  No β2-agonist use on day of screening.&#xD;
&#xD;
               -  No use of inhaled combination asthma therapy on day of screening.&#xD;
&#xD;
               -  Inhaled corticosteroids are allowed on day of screening.&#xD;
&#xD;
          4. Documented reversibility of ≥15% in FEV1 in the screening phase.&#xD;
&#xD;
          5. Demonstrate satisfactory technique in the use of the study medications.&#xD;
&#xD;
          6. Willing and able to enter information in the diary and attend all study visits.&#xD;
&#xD;
          7. Willing and able to substitute study medication for their pre study prescribed asthma&#xD;
             medication for the duration of the study.&#xD;
&#xD;
          8. Written informed consent obtained&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Near fatal or life-threatening (including intubation) asthma within the past year.&#xD;
&#xD;
          2. Hospitalization or an emergency visit for asthma within the past year.&#xD;
&#xD;
          3. History of systemic (oral or parenteral) corticosteroid medication within 1 month&#xD;
             before the Screening Visit.&#xD;
&#xD;
          4. History of omalizumab use within the past 6 months.&#xD;
&#xD;
          5. History of leukotriene receptor antagonist use, e.g. montelukast, or theophylline&#xD;
             within the past week.&#xD;
&#xD;
          6. Current evidence or history of any clinically significant disease or abnormality&#xD;
             including uncontrolled coronary artery disease, congestive heart failure, myocardial&#xD;
             infarction, or cardiac dysrhythmia. 'Clinically significant' is defined as any disease&#xD;
             that, in the opinion of the Investigator, would put the patient at risk through study&#xD;
             participation, or which would affect the outcome of the study.&#xD;
&#xD;
          7. In the investigators opinion a clinically significant upper or lower respiratory&#xD;
             infection within 4 weeks prior to the Screening Visit.&#xD;
&#xD;
          8. Significant, non-reversible, active pulmonary disease (e.g., chronic obstructive&#xD;
             pulmonary disease (COPD), cystic fibrosis, bronchiectasis, tuberculosis).&#xD;
&#xD;
          9. Known Human Immunodeficiency Virus (HIV)-positive status.&#xD;
&#xD;
         10. A smoking history equivalent to &quot;10 pack years&quot; (i.e., at least 1 pack of 20&#xD;
             cigarettes /day for 10 years or 10 packs/day for 1 year, etc.).&#xD;
&#xD;
         11. Current smoking history within 12 months prior to the Screening Visit.&#xD;
&#xD;
         12. Current evidence or history of alcohol and/or substance abuse within 12 months prior&#xD;
             to the Screening Visit.&#xD;
&#xD;
         13. Subjects who have taken B-blocking agents, tricyclic antidepressants, monoamine&#xD;
             oxidase inhibitors, astemizole (Hismanal), quinidine type antiarrhythmics, or potent&#xD;
             CYP 3A4 inhibitors such as ketoconazole within the past week.&#xD;
&#xD;
         14. Current use of medications that will have an effect on bronchospasm and/or pulmonary&#xD;
             function.&#xD;
&#xD;
         15. Current evidence or history of hypersensitivity or idiosyncratic reaction to test&#xD;
             medications or components.&#xD;
&#xD;
         16. Receipt of an investigational drug within 30 days of the Screening Visit (12 weeks if&#xD;
             an oral or injectable steroid).&#xD;
&#xD;
         17. Current participation in a clinical study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kassel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Erd</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cluj-Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chesterfield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/search?query=FLT3505</url>
    <description>Results available on register</description>
  </link>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>November 21, 2007</study_first_submitted>
  <study_first_submitted_qc>November 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2007</study_first_posted>
  <last_update_submitted>October 22, 2018</last_update_submitted>
  <last_update_submitted_qc>October 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Formoterol</keyword>
  <keyword>Fluticasone</keyword>
  <keyword>Asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

